General Information of the Drug (ID: M6APDG04159)
Name
AZD5312
Status
Phase 2
TTD Drug ID
D0C9EN
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Androgen receptor (AR)
ETS-related transcription factor Elf-3 (ELF3)
In total 1 mechanisms lead to this potential drug response
Response Summary Androgen receptor (AR) is a therapeutic target for AZD5312. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of AZD5312 through regulating the expression of Androgen receptor (AR). [1], [2]
References
Ref 1 ELF3 is a repressor of androgen receptor action in prostate cancer cells. Oncogene. 2014 Feb 13;33(7):862-71. doi: 10.1038/onc.2013.15. Epub 2013 Feb 25.
Ref 2 New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol. 2013 Feb;182(2):460-73. doi: 10.1016/j.ajpath.2012.10.029. Epub 2012 Dec 4.